Health Guard plans dual listing to fund HPV vaccine fight
After a Beijing IPO last year, the loss-making biotech has also filed for a Hong Kong listing to better compete in the crowded market for HPV vaccines Key Takeaways: Beijing…
Recent Articles
RELATED ARTICLES
-
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK -
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
